You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation
SBC: IMMUNOPHOTONICS INC Topic: 102Abstract: Immunophotonics is a biotech company developing a synthetic biopolymer, IP-001, to potentiate a systemic immunotherapy via microwave (MWA) thermal tumor ablation for treatment of Hepatocellular carcinoma (HCC). The goal of this SBIR Fast Track is to complete preclinical safety and efficacy testing to support an investigational new drug (IND) application based on the feedback from a meeti ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Open world intelligence through composition of nonparametrics
SBC: Redpoll, LLC Topic: HR0011SB2022411This proposal responds to the direct to the Snap-On Phase 2 SBIR by extending our novel non-parametric Bayesian framework---OTACON: (O)pen world intelligence (T)hrough (A)ugmentation and (Co)mposition of (N)on-parametrics---for novelty detection in open worlds. We build on our advances in composition and inference of non-parametric Bayesian models, and insights from the mathematics of Optimal Tr ...
SBIR Phase II 2023 Department of DefenseDefense Advanced Research Projects Agency -
SBIR CONCEPT AWARD-NANOSPONGE LINKED DCLK1 INHIBITORS FOR THE TARGETED TREATMENT OF CHOLANGIOCARCINOMA
SBC: DCLK1 LLC Topic: NCICA23The proposed product is designed to meet a high unmet medical need for osteosarcoma (OS), a rare pediatric cancer. OS accounts for 2% of childhood cancers (60% of cases occurring in patients who are 10-20 years of age).(1) OS 5-year survival is 70% for non-metastasized disease, 30% for metastasized primarily as a result of its highly metastatic and drug-resistant nature. Cytotoxic chemotherapy and ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Mitofusin Agonists to Treat Neurodegenerative Disease
SBC: Mitochondria in Motion, Inc. Topic: 104Mitofusin agonists for the treatment of neurodegenerative diseases Gerald W Dorn II, MD Mitochondria in Motion, Inc. Washington University in St Louis School of Medicine Abstract: A number of rare neurodegenerative diseases are characterized by mitochondrial fragmentation, dysmotility and dysfunction. Among these are Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease (HD), which cause ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections
SBC: VaxNewMO Topic: NIAIDPROJECT SUMMARY Klebsiella pneumoniae is an encapsulated human pathogen capable of causing a myriad of human infections. Recently, K. pneumoniae has also emerged as one the most common causes of secondary bacterial pneumonia in COVID-19 patients. Over the last 40 years, K. pneumoniae has evolved into two distinct pathotypes, known as classical K. pneumoniae (cKp) and hypervirulent K. pneumoniae (h ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of a Pre-Exposure Vaccine for Population-Level ProtectionAgainst Staphylococcus aureus Infection
SBC: FORWARD DEFENSE, LLC Topic: NIAIDPROJECT SUMMARY Staphylococcus aureus is an aggressive antibiotic-resistant human bacterial pathogen. S. aureus is a leading cause of infectious disease morbidity, mortality, and hospital-associated infection in the U.S., and a formidable health threat worldwide. Given the rapid acquisition of drug resistance by S. aureus, universal vaccination has been a premier goal in the field to provide a dur ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections
SBC: VaxNewMO Topic: NIAIDPROJECT SUMMARY Klebsiella pneumoniae is a leading cause of healthcare- and community-associated infections. Moreover, K. pneumoniae is frequently resistant to last line antibiotics like third generation cephalosporins and carbapenems. In fact, carbapenem-resistant Klebsiella is considered an Urgent Threat by the CDC requiring aggressive, immediate action. One of the five core actions proposed by ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Novel tetrahedron beam CT for point-of-care imaging in ear, nose and throat imaging
SBC: TETRAIMAGING LLC Topic: NIBIBABSTRACT Point-of-care imaging is highly desired in otolaryngologic clinics for the diagnosis of ear, nose and throat (ENT) diseases including cancers. Due to limited image quality, current cone-beam CT (CBCT) products act not as a substitute but rather as a complement to diagnostic Multi-slice CT (MSCT) in maxillofacial and ENT imaging. The emerging multi-source x-ray source technology suggests n ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Wearable modular high-density diffuse optical tomography
SBC: EsperImage LLC Topic: 103Project Summary: EsperImage, a startup company out of Washington University (WUSTL), will develop high fidelity, wearable, optical technology that transcends limitations of both previous optical neuroimaging and magnetic resonance imaging (MRI) tools to provide naturalistic brain imaging in adults and children. A neurodevelopmental disorder affecting 1/54 children in the general population, autism ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Developing a clinical diagnostic tool for age-related cochlear synaptopathy.
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: NIAAge-related hearing loss (ARHL) is the predominant neurodegenerative disease of aging. Recent animal studies have demonstrated that the earliest cochlear pathology due to noise and aging involves a loss of the inner hair cell ribbon synapse. The early consequences of this synaptic loss are not believed to affect hearing sensitivity, but rather, impair speech understanding in background noise. Whil ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health